As part of the annual STAT Summit, PhRMA President and CEO Stephen J. Ubl recently spoke with STAT’s Matthew Herper to discuss the many unintended consequences expected from the latest drug pricing plan on Capitol Hill, as well as the biopharmaceutical industry’s plans to help build a better health care system that improves patient access and protects innovation.
